Bud Genius Launches New Investor Relations Website

Site provides investors with insight into forward progress, newest developments, milestones and achievements

LOS ANGELES--()--Bud Genius, Inc. (www.BGMedTech.com) (OTC: RIGH), a leading laboratory for cannabis testing and profiling, developer of data-driven rating systems for marijuana strains, brand and retail development specialist, and licensee of celebrity-endorsed marijuana and hemp related merchandise, announced today the launch of their new Investor Relations Website.

BGMedTech.com features company news, profiles of the company’s divisions, updates on cannabis legalization efforts, plus media and investor contact information – all in a new, contemporary, and easy-to-navigate website.

Shareholders and investors will be interested in sections on the company’s current and future revenue drivers, including Marijuana Testing and Profiling, Licensing and Branding, Distribution and Supply Chain Optimization, and Healthcare Delivery Technology.

“We have expressed our 2015 growth initiatives to our shareholders and envision the new Investor Relations Website as a gathering place for information and insight on our company,” said Angel Stanz, company CEO. “We are moving fast and expect company news to be evolving rapidly. This site has been developed so that our investors and interested parties can always find the latest information about our forward progress, newest developments, milestones and achievements.”

For more information on Bud Genius, call (855) 723-3283, or visit BGMedTech.com.

About Bud Genius:

An early leader in the cannabis industry, Bud Genius is one of the first established analytical cannabis laboratories in the United States. Bud Genius launched to bring vendors together with doctors, patients, and dispensaries that require certified products held to demanding standards. Bud Genius’ mission is to expand across the US and abroad, serving as the beacon of quality for medical cannabis and adult-use marijuana through the formation of regional laboratories, strain certification, data collection, online reporting, and product development.

For more information please visit: www.BudGenius.com

Forward Looking Statements:

This press announcement includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of company’s management and are subject to significant risks and uncertainties. Forward-looking statements can be identified by such terminology as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations could be affected by, among other things, uncertainties relating to our success in completing acquisitions, financing our operations, entering into strategic partnerships, competitive factors, and other matters. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

Contacts

Bud Genius, Inc.
Angel Stanz
Chief Executive Officer
855-723-3283
PR@BudGenius.com
or
Connect:
Website: www.BudGenius.com
Investors: www.BGMedTech.com
Twitter: Twitter.com/BudGenius

Release Summary

Bud Genius Launches New Investor Relations Website. Site provides investors with insight into forward progress, newest developments, milestones and achievements.

Contacts

Bud Genius, Inc.
Angel Stanz
Chief Executive Officer
855-723-3283
PR@BudGenius.com
or
Connect:
Website: www.BudGenius.com
Investors: www.BGMedTech.com
Twitter: Twitter.com/BudGenius